在最近的一次检查中,林业发展局查明了Gland Pharma的印度设施的三个程序问题。 FDA identifies three procedural issues at Gland Pharma's Indian facility during a recent inspection.

美国食品和药品管理局(FDA)最近在印度Viskhapatnam的Gland Pharma设施进行检查时发现了三个程序性问题。 The U.S. Food and Drug Administration (FDA) found three procedural issues during a recent inspection at Gland Pharma's facility in Visakhapatnam, India. 检查于2月19日至25日进行,重点是无菌活性药物成分。 The inspection, which took place from February 19-25, focused on sterile active pharmaceutical ingredients. 专门研究通用注射器的Gland Pharma表示,这些问题与数据完整性无关,并将按要求提交纠正行动。 Gland Pharma, which specializes in generic injectables, says the issues are not related to data integrity and will submit corrective actions as required.